Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis - Summary - MDSpire

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis

  • By

  • Paul G. Kemps

  • Jennifer L. Picarsic

  • Sébastien Héritier

  • Jean Donadieu

  • Julien Haroche

  • Laure Farnault

  • Stefania Gaspari

  • Dmitry A. Evseev

  • Daria S. Osipova

  • Alexander E. Druy

  • Milen Minkov

  • Susan Picton

  • Andreas Beilken

  • Robert Möhle

  • Miloš B. Kuzmanović

  • Hitomi S. Okuma

  • Chung W. Chow

  • Martin A. Campbell

  • Gregory S. Phillips

  • Yuhang Zhou

  • Gaurav Goyal

  • Ronald S. Go

  • Kee Kiat Yeo

  • Bryan A. Sisk

  • Joanna L. Weinstein

  • Patrick K. Campbell

  • Eli L. Diamond

  • Jean-François Emile

  • April 14, 2026

  • 0 min

Share

Objective:

To evaluate long-term outcomes and remission rates after discontinuation of ALK inhibitors in patients with ALK-positive histiocytosis, highlighting the clinical significance of these findings.

Key Findings:
  • All 27 patients showed objective responses to ALK inhibition, with 56% achieving CR and 44% achieving PR. Sustained remission was observed for a median duration of X months post-cessation.
Interpretation:

The study highlights the potential for long-term remission in ALK-positive histiocytosis patients after stopping ALK inhibitors, suggesting that some patients may not require indefinite treatment, which could impact future treatment strategies.

Limitations:
  • The study is retrospective and may be subject to selection bias, potentially affecting the generalizability of the results.
Conclusion:

ALK inhibition is effective in treating ALK-positive histiocytosis, with many patients achieving long-term remission even after treatment cessation.

Original Source(s)

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis

  • by Paul G. Kemps, Jennifer L. Picarsic, Sébastien Héritier, Jean Donadieu, Julien Haroche, Laure Farnault, Stefania Gaspari, Dmitry A. Evseev, Daria S. Osipova, Alexander E. Druy, Milen Minkov, Susan Picton, Andreas Beilken, Robert Möhle, Miloš B. Kuzmanović, Hitomi S. Okuma, Chung W. Chow, Martin A. Campbell, Gregory S. Phillips, Yuhang Zhou, Gaurav Goyal, Ronald S. Go, Kee Kiat Yeo, Bryan A. Sisk, Joanna L. Weinstein, Patrick K. Campbell, Eli L. Diamond, Jean-François Emile

  • April 14, 2026

Related Content

Computed tomography-derived sarcopenia, enteral nutritional support, and febrile neutropenia burden in children with acute lymphoblastic leukemia: a retrospective cohort study

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation